An integrated medical treatment for type-2 diabetes

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 8, Issue 1, 2014, Pages 57-61

  Bocci, Velio ^a   Zanardi, Iacopo ^b   Huijberts, Maya S P ^a   Travagli, Valter ^a,b  

^a UNIVERSITY OF SIENA   (Italy)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antioxidants; Diabetes; Nrf2 activation; Oxidative stress; Oxygen ozonetherapy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ANTIDIABETIC AGENT; HEXOSAMINE; POLYOL; PROTEIN KINASE C;

ATHEROSCLEROSIS; BIOCHEMISTRY; CHRONIC INFLAMMATION; CHRONIC STRESS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE COURSE; EPIDEMIC; HUMAN; MEDICATION THERAPY MANAGEMENT; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; OZONE THERAPY; PRIORITY JOURNAL; REVIEW;

ANTIOXIDANTS; DIABETES; NRF2 ACTIVATION; OXIDATIVE STRESS; OXYGEN-OZONETHERAPY;

ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; OZONE;

EID: 84897059593     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2013.10.004     Document Type: Review

References (53)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diab Res Clin Pract 2010;87:4-14.
2. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004;10:549-57. (Pubitemid 39433824)
3. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 2006;38:769-89. (Pubitemid 44903268)
4. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011;16:123-40.
5. Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev 2009;29:646-82.
6. Sagai M, Bocci V. Mechanisms of action involved in ozone therapy: is healing induced via a mild oxidative stress? Med Gas Res 2011;1:29. http://dx.doi.org/10.1186/2045-9912-1-29.
7. Bocci V. How a calculated oxidative stress can yield multiple therapeutic effects. Free Radic Res 2012;46:1068-75.
8. Bocci V, Zanardi I, Huijberts MS, Travagli V. Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy. Diab Metab Syndr 2011;5:45-9. http://dx.doi.org/10.1016/j.dsx.2010.05. 014.
9. Brownlee M. A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest 2003;112:1788-90. (Pubitemid 38063700)
10. Haas B, Schlinkert P, Mayer P, Eckstein N. Targeting adipose tissue. Diabetol Metab Syndr 2012;4:43. http://dx.doi.org/10.1186/1758-5996-4-43.
11. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007;50:18-25. (Pubitemid 46035847)
12. Huijberts MS, Schaper NC, Schalkwijk CG. Advanced glycation end products and diabetic foot disease. Diab Metab Res Rev 2008;24(Suppl. 1):S19-24. (Pubitemid 351802767)
13. Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diab Metab Rev 1994;10:189-224. (Pubitemid 24306134)
14. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diab Med 2004;21:203-7. (Pubitemid 38299611)
15. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107.
16. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diab Med 1997;14:29-34. (Pubitemid 27019919)
17. Jialal I, Devaraj S, Venugopal SK. Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy. Free Radic Res 2002;36:1331-6. (Pubitemid 35469520)
18. Lecube A, Pachón G, Petriz J, Hernández C, Simó R. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PLoS ONE 2011;6:e23366. http://dx.doi.org/10.1371/ journal.-pone.0023366.
19. Burut DF, Karim Y, Ferns GA. The role of immune complexes in atherogenesis. Angiology 2010;61:679-89.
20. Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005;54:570-5.
21. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diab Care 2001;24:1433-7. (Pubitemid 33716433)
22. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-12.
23. West IC. Radicals and oxidative stress in diabetes. Diab Med 2000;17:171-80. (Pubitemid 30212288)
24. Nakao A, Sugimoto R, Billiar TR, McCurry KR. Therapeutic antioxidant medical gas. J Clin Biochem Nutr 2009;44:1-13.
25. Timbrell J. In: Timbrell J, editor. The poison paradox chemicals as friends and foes, New York, NY: Oxford University Press; 2005.
26. Jerrett M, Burnett RT, Pope 3rd CA, Ito K, Thurston G, Krewski D, et al. Longterm ozone exposure mortality. N Engl J Med 2009;360:1085-95.
27. Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharmacol 2006;216:493-504. (Pubitemid 44584318)
28. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994;234:279-93.
29. Bocci V. The case for oxygen-ozonetherapy. Br J Biomed Sci 2007;64:44-9. (Pubitemid 46952972)
30. Bocci V, Zanardi I, Travagli V. Oxygen/ozone as a medical gas mixture. A critical evaluation of the various methods clarifies positive and negative aspects. Med Gas Res 2011;1:6. http://dx.doi.org/10.1186/2045-9912-1-6.
31. Mendiratta S, Qu ZC, May JM. Enzyme-dependent ascorbate recycling in human erythrocytes: role of thioredoxin reductase. Free Radic Biol Med 1998;25:221-8. (Pubitemid 28293158)
32. Antunes F, Cadenas E. Estimation of H2O2 gradients across biomembranes. FEBS Lett 2006;475:121-6.
33. Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006;8:243-70. (Pubitemid 43741296)
34. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141-79.
35. Bocci V, Valacchi G, Corradeschi F, Fanetti G. Studies on the biological effects of ozone: 8. Effects on the total antioxidant status and on interleukin-8 production. Mediators Inflamm 1998;7:313-7. (Pubitemid 28552763)
36. Larini A, Bocci V. Effects of ozone on isolated peripheral blood mononuclear cells. Toxicol In Vitro 2005;19:55-61. (Pubitemid 39592977)
37. Valacchi G, Bocci V. Studies on the biological effects of ozone: 10. Release of factors from ozonated human platelets. Mediators Inflamm 1999;8:205-9. (Pubitemid 30019330)
38. Awasthi YC, Ansari GA, Awasthi S. Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferases. Methods Enzymol 2005;401:379-407. (Pubitemid 43052405)
39. Alary J, Guéraud F, Cravedi JP. Fate of 4-hydroxynonenal in vivo: disposition and metabolic pathways. Mol Aspects Med 2003;24:177-87. (Pubitemid 36945018)
40. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, et al. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A 2012;109:17597-602.
41. Calabrese EJ. Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp Toxicol 2010;29:249-61.
42. Bocci V, Zanardi I, Travagli V. Ozone acting on human blood yields a hormetic dose-response relationship. J Transl Med 2011;9:66. http://dx.doi.org/10.1186/1479-5876-9-66.
43. Bocci V, Zanardi I, Michaeli V, Travagli V. Mechanisms of action and chemicalbiological interactions between ozone and body compartments: a critical appraisal of the different administration routes. Curr Drug Ther 2009;4:159-73.
44. Nabuurs-Franssen MH, Sleegers R, Huijberts MS, Wijnen W, Sanders AP, Walenkamp G, et al. Total contact casting of the diabetic foot in daily practice: a prospective follow-up study. Diab Care 2005;28:243-7. (Pubitemid 40170920)
45. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. Delivery of care to diabetic patients with foot ulcers in daily practice: results of the Eurodiale Study, a prospective cohort study. Diab Med 2008;25:700-7. (Pubitemid 351782831)
46. Travagli V, Zanardi I, Bocci V. Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims. Recent Pat Antiinfect Drug Discov 2009;4:130-42.
47. Wainstein J, Feldbrin Z, Boaz M, Harman-Boehm I. Efficacy of ozone-oxygen therapy for the treatment of diabetic foot ulcers. Diab Technol Ther 2011;13:1255-60.
48. Valacchi G, Zanardi I, Sticozzi C, Bocci V, Travagli V. Emerging topics in cutaneous wound repair. Ann N Y Acad Sci 2012;1259:136-44.
49. Ajamieh H, Merino N, Candelario-Jalil E, Menéndez S, Martinez-Sanchez G, Re L, et al. Similar protective effect of ischaemic and ozone oxidative preconditionings in liver ischaemia/reperfusion injury. Pharmacol Res 2002;45:333-9. (Pubitemid 35430529)
50. Foglieni C, Fulgenzi A, Belloni D, Sciorati C, Ferrero E, Ferrero ME. Ozonated autohemotherapy: protection of kidneys from ischemia in rats subjected to unilateral nephrectomy. BMC Nephrol 2011;12:61. http://dx.doi.org/10.1186/ 1471-2369-12-61.
51. El-Sawalhi MM, Darwish HA, Mausouf MN, Shaheen AA. Modulation of age-related changes in oxidative stress markers and energy status in the rat heart and hippocampus: a significant role for ozone therapy. Cell Biochem Funct 2013;31:518-25. http://dx.doi.org/10.1002/cbf.2930.
52. Xu J, Kulkarni SR, Donepudi AC, More VR, Slitt AL. Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. Diabetes 2012;61:3208-18. http://dx.doi.org/10.2337/db11-1716.
53. Xue P, Hou Y, Chen Y, Yang B, Fu J, Zheng H, et al. Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes 2013;62:845-54.